[Form 4] Immuneering Corporation Insider Trading Activity

Rhea-AI Filing Summary

Immuneering Corp. (IMRX) Form 4 filing: On 24 June 2025 the company reported two open-market insider purchases by Chief Scientific Officer Brett Matthew Hall.

• 20 Jun 2025 – Hall bought 7,415 Class A common shares at a weighted-average price of $2.6999.
• 23 Jun 2025 – Hall bought 6,007 Class A common shares at a weighted-average price of $2.4299, with individual trades executed between $2.4101 and $2.4299 (per footnote 1). Both transactions were coded “P,” confirming they were purchases rather than option exercises.

No derivative securities were reported in Table II. Following the purchases Hall now directly owns 359,318 Class A shares, up from 345,896 beforehand—an increase of roughly 3.9 %. The filing does not mark the Rule 10b5-1 safe-harbor box and contains no amendments or dispositions.

Positive

• Chief Scientific Officer Brett Matthew Hall purchased 13,422 Class A shares on 20 Jun 2025 and 23 Jun 2025, indicating insider confidence.
• Hall’s direct ownership increased to 359,318 shares after the transactions, with no accompanying sales or derivative activity.

Negative

• None.

Insights

Securities Analyst

TL;DR: Insider CSO adds 13.4k shares; confidence signal but modest size, unlikely to shift valuation.

The purchases total 13,422 shares at a combined cash outlay of roughly US$34,400, raising Hall’s direct stake to 359,318 shares. Although insider buying is generally viewed as a bullish indicator, the incremental 3.9 % increase is small relative to both Hall’s existing holding and Immuneering’s 28.4 million share float. No derivatives or sales were disclosed, reinforcing the net-buy stance. From a market-impact standpoint the dollar value is minor, so the transaction is best interpreted as a sentiment data point rather than a catalyst for immediate price movement.

Corporate Governance Specialist

TL;DR: Additional ownership strengthens alignment; no 10b5-1 plan noted; overall governance positive but financially immaterial.

The Form 4 shows voluntary, open-market purchases by a named executive officer with no accompanying sales or hedges, enhancing management–shareholder alignment. The absence of a checked 10b5-1 box suggests discretionary timing, which investors often interpret as higher conviction. Compliance appears proper—timely filing, clear footnote disclosure, and no proxy for derivative instruments. From a governance lens this is a constructive data point, yet the nominal dollar amount limits its strategic weight.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hall Brett Matthew

(Last) (First) (Middle)

245 MAIN STREET

SECOND FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [ IMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF SCIENTIFIC OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/20/2025		P		7,415	A	$2.6999	353,311	D
Class A Common Stock	06/23/2025		P		6,007	A	$2.4299(1)	359,318	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.4101 to $2.4299. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

Remarks:

	/s/ Michael D. Bookman, Attorney-in-Fact for Brett Matthew Hall	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many IMRX shares did CSO Brett Hall purchase on 20 June 2025?

He acquired 7,415 Class A common shares.

What was the weighted-average price paid for IMRX shares on 23 June 2025?

The weighted-average purchase price was $2.4299 per share.

What is Brett Hall’s total direct ownership in IMRX after the purchases?

He now owns 359,318 Class A common shares directly.

Were any derivative securities involved in Brett Hall’s recent transactions?

No. Table II lists no derivative securities acquired or disposed.

Which SEC form disclosed these insider transactions for Immuneering (IMRX)?

The transactions were reported on Form 4.